1 Recert-Free standing (Orphan Drug)

OPA 340B Database - (v4.0.0.20 - UAT)

Page 1 of 2

500002 | Logout | Help

Home

Covered Entities ▼

Contract Pharmacies ▼

Manufacturers ▼

Reports

Covered Entity Details
Edit
340B ID:
Entity Name:

RRC500002-00

PROVIDENCE ST. MARY MEDICAL
CENTER

Entity Type: Rural Referral Center
Grant Number:

Entity Sub-Division Name:
Medicare Provider Number: 500002

Covered Entity Address
Main Address (PO Box Not Allowed)

Edit

401 WEST POPLAR ST.
WALLA WALLA, WA 99362

 Billing




Billing Address
Address Same
Same as
as Main
Main
Billing Address
PROVIDENCE ST. MARY MEDICAL CENTER
PO BOX 1477
WALLA WALLA, WA 99362

 Shipping Address Same as





as Main
Main

Covered Entity Date Information
Edit
Registration Date:

8/4/2010

Participating Start Date:

Participating Approval Date:

8/4/2010

Termination Reason:

8/11/2010

Termination Date:

Comments:

Qualification Information
Edit

 Entity is a Rural Referral Center defined by section 1886(d)(5)(C)(i) of the Social Security Act, and this status is recognized by CMS





Disproportionate Share Adjustment Percentage: 10.24%
Cost Reporting Period From: 1/1/2009 to 12/31/2009
Hospital Classification: Private, Non-Profit Hospital with State/Local Govt Contract

Medicaid Billing Information
Edit
You must answer the following question regarding Medicaid Billing:
Will you bill Medicaid for drugs purchased at 340B drug price?





 Yes 

 No




Medicaid Number(s):

Medicaid Number

State

3303104

WA

NPI Number(s):

NPI Number
1386895890

http://opauat.primescapesolutions.net/OPA_MOD_UAT/PM_CEDetails.aspx?InitiativeEnt... 4/30/2012

OPA 340B Database - (v4.0.0.20 - UAT)

Page 2 of 2

Orphan Drug Exclusion:
340B hospitals subject to the orphan drug exclusion (i.e., critical access hospitals,
free-standing cancer hospitals, sole community hospitals and rural referral centers) are responsible for ensuring
that any orphan drugs purchased through the 340B Program are not transferred, prescribed, sold, or otherwise used
for the rare condition or disease for which the orphan drugs are designated under section 526 of the Federal Food,
Drug, and Cosmetic Act. Please choose one of the following:
I. The hospital will purchase orphan drugs under the 340B Program and maintain auditable records to
demonstrate compliance with the orphan drug exclusion.
II. The hospital cannot or does not wish to maintain auditable records regarding compliance with the orphan
drugs exclusion and will purchase all orphan drugs outside of the 340B Program regardless of the indication
for which the drug is used and will not use a Group Purchasing Organization (GPO) to purchase those drugs if
the hospital is a free-standing cancer hospital.

Certify

Decertify

Cancel

HHS Privacy Policy Notice
U.S. Department of Health and Human Services (HHS)
Health Resources and Services Administration (HRSA)
Office of Pharmacy Affairs (OPA) - 340B Program

April 30, 2012
3:31 PM ET

Questions, Comments, or Suggestions
Email Us: [email protected]
Call Us: 1 - 800 - 628 - 6297




Contact Information
Authorizing Official
Name:
Title:
Phone:
Email:

Edit
MICHAEL PARENTEAU
CHIEF FINANCIAL OFFICER
509-522-5890 Ext:
[email protected]

 Make Primary




Primary Contact
Contact Information
Information same
same as
as Authorizing
Authorizing Official
Official
Primary Contact
Name:
Title:
Phone:
Email:

ANITA TREIS
DIRECTOR, PHARMACY OPERATIONS
509-522-5894 Ext:
[email protected]

http://opauat.primescapesolutions.net/OPA_MOD_UAT/PM_CEDetails.aspx?InitiativeEnt... 4/30/2012

The undersigned represents and confirms that he/she is fully authorized to legally bind the covered entity and
certifies that the contents of any statement made or reflected in this document are truthful and accurate. Failure
to recertify may be grounds for removal from the 340B Program.
The undersigned further acknowledges the 340B covered entity’s responsibility to abide by the following:
As an Authorized Official, I certify on behalf of the covered entity that:
(1) all information listed on the 340B Program database for the covered entity is complete, accurate, and
correct;
(2) the covered entity meets all 340B Program eligibility requirements, including (if applicable) section 340B(a)(4)(L)(iii)
and the Statutory Prohibition on Group Purchasing Organization Participation Policy Release 2013-1which ensures that the
covered entity hospital does not obtain covered outpatient drugs through a group purchasing
organization or other group purchasing arrangement;
(3) the covered entity is complying with all requirements and restrictions of Section 340B of the Public Health
Service Act and any accompanying regulations or guidelines including, but not limited to, the prohibition against
duplicate discounts/rebates under Medicaid, and the prohibition against transferring drugs purchased under
340B to anyone other than a patient of the entity; The covered entity will comply with all requirements and restrictions
of Section 340B of the Public Health Service Act and any accompanying regulations or guidelines including, but not
limited to, the prohibition against duplicate discounts/rebates under Medicaid, the prohibition against transferring drugs
purchased under 340B to anyone other than a patient of the entity, and the exclusion of orphan drugs for free standing cancer
hospitals.
(4) the covered entity maintains auditable records demonstrating compliance with the requirements described above;
(5) the covered entity has systems/mechanisms in place to ensure ongoing compliance with the requirements
described above;
(6) if the covered entity uses contract pharmacy services, that the contract pharmacy arrangement is being
performed in accordance with OPA requirements and guidelines including, but not limited to, that the covered
entity obtains sufficient information from the contractor to ensure compliance with applicable policy and legal
requirements, and the hospital has utilized an appropriate methodology to ensure compliance (e.g., through an
independent audit or other mechanism);
(7) the covered entity acknowledges its responsibility to contact OPA as soon as reasonably possible if there is
any material change in 340B eligibility and/or material breach by the covered entity of any of the foregoing; and
(8) the covered entity acknowledges that if there is a breach of the requirements described above that
the covered entity may be liable to the manufacturer of the covered outpatient drug that is the subject of the
violation, and, depending upon the circumstances, may be subject to the payment of interest and/or removal
from the list of eligible 340B entities.
Signature of Authorizing Official:

Date:

__________________________________________________________________________________